UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Position in Evolent Health, Inc. (NYSE:EVH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Evolent Health, Inc. (NYSE:EVH - Free Report) by 13.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,364,298 shares of the technology company's stock after selling 210,301 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 1.17% of Evolent Health worth $38,582,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in EVH. Royce & Associates LP acquired a new stake in Evolent Health in the third quarter valued at approximately $7,070,000. Foundry Partners LLC acquired a new stake in Evolent Health in the 3rd quarter valued at $10,042,000. Harbor Capital Advisors Inc. increased its stake in Evolent Health by 140.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company's stock valued at $11,946,000 after purchasing an additional 246,400 shares in the last quarter. Valeo Financial Advisors LLC bought a new stake in Evolent Health during the 2nd quarter valued at $2,705,000. Finally, Engaged Capital LLC raised its holdings in Evolent Health by 26.1% during the second quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company's stock worth $78,611,000 after buying an additional 850,000 shares during the last quarter.

Analyst Ratings Changes

Several research firms have recently commented on EVH. Citigroup decreased their target price on shares of Evolent Health from $33.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. JMP Securities lowered their price objective on Evolent Health from $34.00 to $31.00 and set a "market outperform" rating for the company in a research note on Friday, August 9th. KeyCorp began coverage on Evolent Health in a research report on Friday, October 11th. They set an "overweight" rating and a $35.00 target price on the stock. Stephens downgraded Evolent Health from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $38.00 to $16.00 in a report on Friday, November 8th. Finally, BTIG Research dropped their price objective on Evolent Health from $36.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $26.18.

Evolent Health Price Performance

Shares of Evolent Health stock traded down $0.19 during trading on Wednesday, hitting $11.52. The stock had a trading volume of 4,067,947 shares, compared to its average volume of 1,814,423. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -12.87 and a beta of 1.45. Evolent Health, Inc. has a 12 month low of $11.17 and a 12 month high of $35.00. The business's 50-day moving average is $20.77 and its 200 day moving average is $23.18. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.